Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
AstraZeneca
Merck
McKesson
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Marizomib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Marizomib: Sponsors, patents, clinical trial progress

Marizomib is an investigational drug.

There have been 9 clinical trials for Marizomib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2018.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Glioblastoma, and Multiple Myeloma. The leading clinical trial sponsors are Triphase Research and Development I Corporation, National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.

There are two hundred and seventy-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Marizomib
TitleSponsorPhase
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaNational Cancer Institute (NCI)Phase 2
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaCelgenePhase 3
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 3

See all Marizomib clinical trials

Clinical Trial Summary for Marizomib

Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib

See all Marizomib clinical trials

US Patents for Marizomib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Marizomib   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
Marizomib   Start Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Marizomib   Start Trial Methods and compositions for inhibition of Ras ARAXES PHARMA LLC (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
Medtronic
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.